Hansa Biopharma to host conference call to provide Year-End report 2019 and Business Update

Report this content

Lund, Sweden January 22, 2020. Hansa Biopharma will publish its Year-End report 2019 at 8:00 a.m. CET on February 6, 2020. All interested parties are invited to participate in a telephone conference, which will include a presentation of the interim results and a business update, on the same date at 2:00 p.m. CET. The event will be hosted by Hansa Biopharma’s CEO, Søren Tulstrup, and CFO, Donato Spota, and the presentation will be held in English.

Slides used in the presentation will be live on the company website during the call under “Events & Webcast,” and will also be made available online after the call. To participate in the telephone conference, please use the dial-in details provided below:

Dial-in numbers for participants:
SE: +46 8 50 55 83 56 
UK: +44 333 30 09 260 
US: +1 833 82 30 586

For additional international numbers, please refer to the complete list on website.

The webcast will be available on hansa.eventcdn.net/2019fy/
 

For further information, please contact:
Klaus Sindahl, Head of Investor Relations
Hansa Biopharma
Mobile: +46 (0) 709-298 269
E-mail: klaus.sindahl@hansabiopharma.com

Rolf Gulliksen, Head of Corporate Communications
Hansa Biopharma
Mobile: +46 (0) 733-328 634
E-mail: rolf.gulliksen@hansabiopharma.com

About Hansa Biopharma
Hansa Biopharma is leveraging its proprietary immunomodulatory enzyme technology platform to develop treatments for rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection and cancer. The Company’s lead product candidate, imlifidase, is a unique antibody-cleaving enzyme that potentially may enable kidney transplantation in highly sensitized patients with potential for further development in other solid organ transplantation and acute autoimmune indications. Imlifidase is currently under review for marketing authorization by EMA. Hansa’s research and development program is advancing the next generation of the Company’s technology to develop novel IgG-cleaving enzymes with lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology. Hansa Biopharma is based in Lund, Sweden and also has operations in Europe and US.